• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡咯烷生物碱诱导的肝窦阻塞综合征经颈静脉肝内门体分流术后预后不良的危险因素。

Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.

机构信息

Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321#, Zhongshan Road, Nanjing, 210008, Jiangsu, China.

Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.

出版信息

Hepatol Int. 2021 Jun;15(3):720-729. doi: 10.1007/s12072-020-10126-x. Epub 2021 Jan 28.

DOI:10.1007/s12072-020-10126-x
PMID:33507485
Abstract

AIMS

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective method in treating patients with severe hepatic sinusoidal obstruction syndrome induced by pyrrolidine alkaloids (PA-HSOS). However, some patients still have poor postoperative prognosis. So, we aim to evaluate the predictors associated with poor outcomes in PA-HSOS patients receiving TIPS.

METHODS

Patients who were diagnosed as PA-HSOS and received TIPS in our hospital between January 2013 and April 2019 were reviewed retrospectively. Baseline information and clinical data were collected. The hazard ratios (HRs) of factors associated with poor prognosis were analyzed by Cox proportional hazard analysis. The Kaplan-Meier method was used to analyze and compare the cumulative incidence of the poor results and survival rate of patients.

RESULTS

During a median of 19.25-month follow-up, death occurred in 17 patients. We found that prothrombin time at baseline with an adjusted HR 1.110 (95% confidence interval 1.014-1.216, p = 0.024) and serum total bilirubin of 9 mg/dl 5 days after TIPS with an adjusted HR 1.114 (95% confidence interval 1.042-1.190, p = 0.001) were independent risk factors for death. The 1-year and 5-year survival rate were 86.2% and 82.1%, respectively. The 1-year survival rate in patients with prothrombin time > 17.85 s at baseline and serum total bilirubin > 9 mg/dl at 5 days after TIPS was significantly lower than that of patients below the corresponding threshold, respectively.

CONCLUSIONS

Prolonged prothrombin time at baseline and increased serum total bilirubin levels 5 days after TIPS are independent risk factors for predicting death after TIPS treatment in PA-HSOS patients.

摘要

目的

经颈静脉肝内门体分流术(TIPS)是治疗吡咯烷生物碱(PA)-肝窦阻塞综合征(HSOS)引起的严重肝窦阻塞综合征患者的有效方法。然而,一些患者术后预后仍较差。因此,我们旨在评估 TIPS 治疗 PA-HSOS 患者不良预后的相关预测因素。

方法

回顾性分析 2013 年 1 月至 2019 年 4 月在我院诊断为 PA-HSOS 并接受 TIPS 治疗的患者。收集基线信息和临床资料。采用 Cox 比例风险分析分析与不良预后相关的因素的风险比(HR)。采用 Kaplan-Meier 法分析比较患者不良结果和生存率的累积发生率。

结果

在中位随访 19.25 个月期间,17 例患者死亡。我们发现,TIPS 前的基线凝血酶原时间调整后的 HR 为 1.110(95%置信区间 1.014-1.216,p=0.024)和 TIPS 后 5 天的血清总胆红素 9mg/dl 调整后的 HR 为 1.114(95%置信区间 1.042-1.190,p=0.001)是死亡的独立危险因素。1 年和 5 年生存率分别为 86.2%和 82.1%。TIPS 前凝血酶原时间>17.85s 和 TIPS 后 5 天血清总胆红素>9mg/dl 的患者的 1 年生存率明显低于相应阈值以下的患者。

结论

基线凝血酶原时间延长和 TIPS 后 5 天血清总胆红素水平升高是预测 PA-HSOS 患者 TIPS 治疗后死亡的独立危险因素。

相似文献

1
Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.吡咯烷生物碱诱导的肝窦阻塞综合征经颈静脉肝内门体分流术后预后不良的危险因素。
Hepatol Int. 2021 Jun;15(3):720-729. doi: 10.1007/s12072-020-10126-x. Epub 2021 Jan 28.
2
Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.经颈静脉肝内门体分流术治疗菊三七相关性肝窦阻塞综合征的获益:倾向评分匹配分析。
Cardiovasc Intervent Radiol. 2023 Jul;46(7):931-942. doi: 10.1007/s00270-023-03451-9. Epub 2023 May 24.
3
[Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt].经颈静脉肝内门体分流术治疗肝小静脉闭塞病严重程度分级对患者预后的预测研究
Zhonghua Gan Zang Bing Za Zhi. 2021 Jan 20;29(1):46-53. doi: 10.3760/cma.j.cn501113-20201213-00651.
4
Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.经颈静脉肝内门体分流术治疗与紫背天葵食用相关的肝窦阻塞综合征
BMC Gastroenterol. 2021 Jan 10;21(1):26. doi: 10.1186/s12876-021-01599-7.
5
Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.经颈静脉肝内门体分流术治疗吡咯里西啶生物碱相关肝窦阻塞综合征。
World J Gastroenterol. 2020 Jun 28;26(24):3472-3483. doi: 10.3748/wjg.v26.i24.3472.
6
Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study.经颈静脉肝内门体分流术治疗吡咯里西啶生物碱诱导的肝窦阻塞综合征:一项回顾性队列研究。
Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):1004-1011. doi: 10.1097/MEG.0000000000002591. Epub 2023 Jun 16.
7
Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt : Transjugular intrahepatic portosystemic shunt in patients with sinusoidal obstruction syndrome, etiology matters.经颈静脉肝内门体分流术后吡咯烷生物碱诱导的肝窦阻塞综合征患者预后不良的危险因素:肝窦阻塞综合征患者的经颈静脉肝内门体分流术,病因很重要。
Hepatol Int. 2021 Jun;15(3):568-570. doi: 10.1007/s12072-021-10166-x. Epub 2021 Mar 17.
8
Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.经颈静脉肝内门体分流术与抗凝治疗吡咯里西啶生物碱所致肝窦阻塞综合征的中长期疗效比较
Eur J Gastroenterol Hepatol. 2023 Apr 1;35(4):445-452. doi: 10.1097/MEG.0000000000002509. Epub 2023 Jan 5.
9
Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征患者经颈静脉肝内门体分流术的时机和疗效。
Sci Rep. 2021 Nov 5;11(1):21743. doi: 10.1038/s41598-021-01201-w.
10
Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.紫背天葵致肝小静脉闭塞病的危险因素:一项回顾性研究
BMC Gastroenterol. 2018 Oct 26;18(1):156. doi: 10.1186/s12876-018-0879-7.

引用本文的文献

1
Serum ascites albumin gradient in predicting the severity of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.血清腹水白蛋白梯度在预测由吡咯里西啶生物碱引起的肝窦阻塞综合征严重程度中的作用
Clin Exp Hepatol. 2025 Jun;11(2):152-159. doi: 10.5114/ceh.2025.151628. Epub 2025 Jun 26.
2
Efficacy and safety of transjugular intrahepatic portosystemic shunt in hepatic sinusoidal obstruction syndrome: systematic review and meta-analysis.经颈静脉肝内门体分流术治疗肝窦阻塞综合征的疗效与安全性:系统评价与Meta分析
Front Med (Lausanne). 2025 Aug 13;12:1625825. doi: 10.3389/fmed.2025.1625825. eCollection 2025.
3
Gut microbiota promotes macrophage M1 polarization in hepatic sinusoidal obstruction syndrome via regulating intestinal barrier function mediated by butyrate.
肠道微生物群通过调控丁酸介导的肠道屏障功能促进肝窦阻塞综合征中巨噬细胞 M1 极化。
Gut Microbes. 2024 Jan-Dec;16(1):2377567. doi: 10.1080/19490976.2024.2377567. Epub 2024 Jul 16.
4
Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study.经颈静脉肝内门体分流术治疗由吡咯里西啶生物碱引起的肝窦阻塞综合征:一项多中心回顾性研究
Heliyon. 2023 Dec 8;10(1):e23455. doi: 10.1016/j.heliyon.2023.e23455. eCollection 2024 Jan 15.
5
Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.经颈静脉肝内门体分流术治疗菊三七相关性肝窦阻塞综合征的获益:倾向评分匹配分析。
Cardiovasc Intervent Radiol. 2023 Jul;46(7):931-942. doi: 10.1007/s00270-023-03451-9. Epub 2023 May 24.
6
Agreement between Wedged Hepatic Venous Pressure and Portal Pressure in Hepatic Sinusoidal Obstruction Syndrome.肝窦阻塞综合征中肝静脉楔压与门静脉压力的相关性
J Pers Med. 2022 Dec 20;13(1):4. doi: 10.3390/jpm13010004.
7
Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.建立吡咯里西啶生物碱肝窦阻塞综合征鼓室严重程度评分(DTSS)系统。
Hepatol Int. 2022 Jun;16(3):669-679. doi: 10.1007/s12072-021-10293-5. Epub 2022 Jan 12.